Improving Patient Outcomes in Atrial Fibrillation and Coronary Artery Disease

Patients diagnosed with atrial fibrillation (Afib) and stable coronary artery disease (CAD) face challenges in managing their conditions effectively. However, a recent study, EPIC-CAD, has shown promising results with edoxaban (Savaysa) monotherapy as compared to dual antithrombotic therapy. The trial demonstrated improved net outcomes by considering both bleeding and ischemic events over a 12-month period. Patients receiving edoxaban monotherapy experienced a 0.44 hazard ratio (HR) compared to those on dual antithrombotic therapy, showcasing a significant reduction in adverse events (95% CI 0.30-0.65, P